WHAT IS CLAIMED IS:

[Claim 1]. A Composition which targets 10 to 25-nt contiguous target sequence in a TATA-box region or an enhancer region of a PLP1 gene for use in treating a disease caused by overexpression of the PLP1 gene in a eukaryotic cell, comprising:

a guide RNA including a guide domain and a backbone or nucleic acid encoding the guide RNA, and

a Cas9 protein originated from *Streptococcus pyogenes* or *Campylobacter jejuni*, or a nucleic acid encoding the Cas9 protein,

wherein the guide domain and the backbone is linked sequentially from 5' to 3' direction,

wherein the guide domain is capable of targeting 10 to 25-nt contiguous target sequence in the TATA-box region or the enhancer region of the PLP1 gene,

wherein when the Cas9 protein is originated from *Campylobacter jejuni*, the backbone has a sequence compising 90% or more sequence identity with 5'-GUUUUAGUCCCUGAAAAGGGACUAAAAUAAAGAGUUUGCGGGACUCUGCGGGGUUACAAUCCCCUAAAACCGCUUUU-3' (SEQ ID NO: 295), and the target sequence is selected from SEQ ID NOs: 94 to 115,

wherein when the Cas9 protein is originated from *Streptococcus pyogenes*, a sequence of the backbone has 90% or more sequence identity with 5'-GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC-3' (SEQ ID NO: 296), and the target sequence is selected from SEQ ID NOs: 56 to 93.

[Claim 2]. A composition which targets 10 to 25-nt contiguous target sequence in a TATA-box region or an enhancer region of a PLP1gene for use in treating a disease,

comprising:

a double-stranded guide RNA including a crRNA, and a tracrRNA,

wherein the crRNA comprises a guide domain and a first complementary domain,

wherein the guide domain and the first complementary domain are linked sequentially from 5' to 3'-end,

wherein the tracrRNA comprises a second complementary domain and a proximal domain, and a tail domain,

wherein the second complementary domain, the proximal domain, and the tail domain are linked sequentially from 5' to 3'-end; and

a Cas9 protein originated from *Streptococcus pyogenes* or *Campylobacter jejuni*, or a nucleic acid encoding the Cas9 protein,

wherein the guide domain is capable of targeting 10 to 25-nt contiguous target sequence in the TATA-box region or the enhancer region of the duplicate gene,

wherein when the Cas9 protein is originated from *Campylobacter jejuni*, a first complementary domain is 90% or more identical with 5'-GUUUUAGUCCCUUUUUAAAUUUCUU-3' (SEQ ID NO: 265), the second complementary domain has a sequence compising 90% or more sequence identity with 5'-AAGAAAUUUAAAAAGGGACUAAAAU-3' (SEQ ID NO: 267), the proximal domain is 90% or more identical with 5'-AAAGAGUUUGC-3' (SEQ ID NO: 270), and the tail domain has a sequence compising 90% or more sequence identity with 5'-GGGACUCUGCGGGGUUACAAUCCCCUAAAACCGCUUUU-3' (SEQ ID NO: 272), and the target sequence is selected from SEQ ID NOs: 94 to 115,

wherein when the Cas9 protein is originated from *Streptococcus pyogenes*, the first complementary domain has a sequence compising 90% or more sequence identity with 5'-GUUUUAGAGCUA-3' (SEQ ID NO: 264), the second complementary domain has a sequence compising 90% or more sequency identity with 5'-UAGCAAGUUAAAAU-3' (SEQ ID NO:

266), the proximal domain has a sequence compising 90% or more sequence identity with 5'-AAGGCUAGUCCG-3' (SEQ ID NO: 269), and the tail domain has a sequence compising 90% or more sequency identity with 5'-UUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC-3' (SEQ ID NO: 271), and the target sequence is selected from SEQ ID NOs: 56 to 93.

[Claim 3]. The composition for use according to claim 1 or 2,

wherein the guide RNA and the Cas9 protein in a form of a ribonucleoprotein.

[Claim 4]. The composition for use according to claim 1 or 2,

wherein the composition comprises the nucleic acid encoding the nucleic acid encoding the Cas9 protein.

[Claim 5]. The composition for use according to claim 4,

wherein the composition is in a form of one or more vectors.

[Claim 6]. A guide RNA which target a TATA-box region or an enhancer region of a duplicate gene, for use in treating a disease caused by overexpression of the duplicate gene, comprising:

a guide domain capable of targeting a sequence selected from SEQ ID NOs: 56 to 93; and

a backbone comprising a sequence having 90% or more sequence identity with a sequence 5'-GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC-3' (SEQ ID NO: 296),

wherein the guide domain and the backbone are linked sequentially from 5' to 3'-end,

wherein the duplicate gene is a human PLP1 gene.

[Claim 7]. A double-stranded guide RNA which targets a TATA-box region or an enhancer region of duplicate gene for use in treating a disease caused by overexpression of a

duplicated gene, comprising:

a crRNA comprising a guide domain capable of targeting a sequence selected from SEQ ID NOs: 56 to 93, and a first complementary domain having 90% or more sequence identity with 5'-GUUUUAGAGCUA-3' (SEQ ID NO: 264),

wherein the guide domain and the first complementary domain are linked sequentially from 5' to 3'-end; and

a tracrRNA comprising a second complementary domain having 90% or more sequence identity with 5'-UAGCAAGUUAAAAU-3' (SEQ ID NO: 266), and a proximal domain having 90% or more sequence identity with 5'-AAGGCUAGUCCG-3' (SEQ ID NO: 269), and a tail domain having 90% or more sequence identity with 5'-UUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC-3' (SEQ ID NO: 271),

wherein the second complementary domain, the proximal domain, and the tail domain are linked sequentially from 5' to 3'-end,

wherein the duplicate gene is a human PLP1 gene.

[Claim 8]. A guide RNA which targets an enhancer region of a duplicate gene for use in treating a disease caused by overexpression of a duplicated gene, comprising:

a guide domain capable of targeting a sequence selected from SEQ ID NOs: 94 to 115; and

a backbone having 90% or more sequence identity with a sequence 5'-GUUUUAGUCCCUGAAAAGGGACUAAAAUAAAGAGUUUGCGGGACUCUGCGGGGUUACAAUCCCCUAAAACCGCUUUU-3' (SEQ ID NO: 295),

wherein the guide domain and the backbone are linked sequentially from 5' to 3'-end of the guide RNA,

wherein the duplicate gene is a human PLP1 gene.

[Claim 9]. A double-stranded guide RNA which targets an enhancer region of duplicate gene for use in treating a disease caused by overexpression of a duplicated gene, comprising:

a crRNA comprising a guide domain capable of targeting a sequence selected from SEQ ID NOs: 94 to 115, and a first complementary domain 90% or more identical with 5'-GUUUUAGUCCCUUUUUAAAUUUCUU-3' (SEQ ID NO: 265),

wherein the guide domain and the first complementary domain are linked sequentially from 5' to 3'-end; and

a tracrRNA comprising a second complementary domain having 90% or more sequence identity with 5'-AAGAAAUUUAAAAAGGGACUAAAAU-3' (SEQ ID NO: 267), and a proximal domain having 90% or more sequence identity with 5'-AAAGAGUUUGC-3' (SEQ ID NO: 270), and a tail domain having 90% or more sequence identity with 5'-GGGACUCUGCGGGGUUACAAUCCCCUAAAACCGCUUUU-3' (SEQ ID NO: 272),

wherein the second complementary domain, the proximal domain, and the tail domain are linked sequentially from 5' to 3'-end,

wherein the duplicate gene is a human PLP1 gene.

[Claim 10]. A nucleic acid encoding the guide RNA according to any one of claims 6 to 9.